Summary
The pharmacokinetics of ketanserin (R 41468), a novel serotonin S2-receptor blocking agent widely investigated for its effect on acute and chronic hypertension, has been studied in 10 healthy male subjects. They received single 10 mg doses i.v. and i.m., and 20, 40 and 60 mg solutions of ketanserin by mouth, in a five-way cross-over design. The model-independent kinetics of i.v. ketanserin were characterized by a terminal half-life of 14.3±4.4 h, a moderate plasma clearance (CL=565±57 ml/min) and a large tissue distribution (Vss=268±71 l, Vz=703±204 l; mean ± SD). Following i.m. administration, peak levels of nearly 200 ng/ml were attained within 10 minutes and the absolute bioavailability was 112±23%. After oral dosing, peak levels of ketanserin were reached within 1 h. The peak level and AUC increased in proportion to the dose. The absolute bioavailability was 46.8, 50.4 and 55.5% for 20, 40 and 60 mg doses and they conformed to the predicted bioavailability based on i.v. clearance data. The terminal half-life of 17 h and the urinary excretion of parent drug (about 0.7% of the dose) were similar after oral and parenteral dosing. The kinetics of ketanserin-ol, the major metabolite of ketanserin formed by ketone reduction, was also studied. Because of its negligible pharmacological activity, the contribution of ketanserin-ol to the overall therapeutic effect of ketanserin is small, in spite of its 1.6-times (parenteral) to 3.2-times (oral) higher plasma level than that of ketanserin. The particular role of the metabolite is discussed in the light of the clinical pharmacokinetics of ketanserin.
Similar content being viewed by others
References
Janssen PAJ (1985) Pharmacology of potent and selective S2-serotonergic antagonists. J Cardiovasc Pharmacol 7 [Suppl 7]: S2-S11
Van Nueten J, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren T, Vanhoutte P (1981) Vascular effects of ketanserin (R41468), a novel antagonist of 5HT2-serotonergic receptors. J Pharmacol Exp Ther 218: 217–230
Leysen J, Awouters F, Kennis L, Laduron P, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R41468, a novel antagonist at 5-HT2-receptors. Life Sci 28: 1015–1022
De Cree J, Verhaegen H, Symoens J (1981) Acute blood-pressure-lowering effect of ketanserin. Lancet 1: 1161–1162
Wenting GJ, Woittiez AJJ, Man In't Veld AJ, Schalekamp MADH (1984) 5-HT, alpha-adrenoreceptors and blood-pressure effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6: 100–109
Vanhoutte PM, Van Nueten JM, Symoens J, Janssen PAJ (1983) Antihypertensive properties of ketanserin (R41468). Fed Proc 42: 182–185
De Cree J, Hoing M, De Ryck M, Symoens J (1985) The acute antihypertensive effect of ketanserin increases with age. J Cardiovasc Pharmacol 7 [Suppl 7]: S126-S127
De Cree J, Leempoels J, Geukens H, Verhaegen H (1984) Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. Lancet 2: 775–779
Roald OK, Seem E (1984) Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J 289: 577–579
Reimann I, Okonkwo P, Klotz U (1983) Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol 25: 73–76
Trenk D, Mosler A, Kirch W, Meinertz T, Jähnchen E (1983) Pharmacokinetics and pharmacodynamics of the 5-HT2-receptor antagonist ketanserin in man. J Cardiovasc Pharmacol 5: 1034–1039
Kurowski M (1985) Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol 28: 411–417
Meuldermans W, Hendrickx J, Lauwers W, Swysen E, Hurkmans R, Knaeps F, Woestenborghs R, Heykants J (1984) Excretion and biotransformation of ketanserin after oral and intravenous administration in rats and dogs. Drug Metab Dispos 12: 772–781
Meuldermans W, Hendrickx J, Lauwers W, Hurkmans R, Swysen E, Heykants J (1985) Plasma levels, excretion and biotransformation of ketanserin after a single oral dose in rats, dogs and man. Arch Int Pharmacodyn 274: 330
Frenken M, Kaumann A (1984) Interaction of ketanserin and its metabolite ketanserin-ol with 5-HT2-receptors in pulmonary and coronary arteries of calf. Naunyn Schmiedebergs Arch Pharmacol 326: 334–339
Van Peer A, Woestenborghs R, Heykants J (1986) Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man: Existence of a reduction-oxidation equilibrium. Eur J Clin Pharmacol 31: 339–342
Okonkwo P, Reimann I, Woestenborghs R, Klotz U (1983) High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr 272: 411–416
Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York
SAS User's Guide (1979) SAS Institute GmbH, Heidelberg, FRG (version 82.4)
Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074
Wagner J (1983) Significance of ratios of different volumes of distribution in pharmacokinetics. Biopharm Drug Dispos 4: 263–270
Shand DG (1982) Presystemic hepatic drug elimination in cirrhosis. In: George CF, Shand DG, Renwick AG (eds) Presystemic drug elimination. Butterworths, London
Ritschel WA (1982) The effect of aging on pharmacokinetics: A scientist's view of the future. Contemp Pharmac Pract 5: 209–217
O'Malley K, Crooks J, Duke E, Stevenson IH (1971) Effect of age and sex on human drug metabolism. Br Med J 3: 607–609
Hedner T, Persson B, Berglund G (1983) Ketanserin, a novel 5-hydroxytryptamine antagonist: Monotherapy in essential hypertension. Br J Clin Pharmacol 16: 121–125
Hedner T, Persson B (1984) Ketanserin in combination with β-adrenergic receptor blocking agents in the treatment of essential hypertension. Br J Clin Pharmacol 18: 765–771
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heykants, J., Van Peer, A., Woestenborghs, R. et al. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 31, 343–350 (1986). https://doi.org/10.1007/BF00981135
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00981135